TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors

NCT07266298 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Metastatic Tumor

Interventions

BIOLOGICAL: NW-101C

Sponsor

Neowise Biotechnology